Study guide

Paraneoplastic retinopathy, treatment effects and counselling

European Board of Ophthalmology Diploma EBOD

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: EBOD Examination, Applications and Regulations

EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals

2 Chapter 2: Physical Optics, Photometry and Lenses

Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid

3 Chapter 3: Instrument Optics, Aberrations and Laser Physics

Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT

4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing

Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses

5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation

Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics

6 Chapter 6: Extraocular Anatomy and Motor Physiology

Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys

7 Chapter 7: Binocular Vision and Amblyopia

Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment

8 Chapter 8: Childhood Assessment and Strabismus Testing

Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts

9 Chapter 9: Esotropia, Exotropia and Vertical Deviations

Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew

10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery

Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles

11 Chapter 11: ROP and Paediatric Ocular Disease

Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding

12 Chapter 12: Ocular Surface Anatomy and Infection

Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis

13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation

Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis

14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies

Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies

15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure

Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency

16 Chapter 16: Surface Reconstruction and Keratoplasty

Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems

17 Chapter 17: Lens Development, Cataract Assessment and Biometry

Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry

18 Chapter 18: IOL Planning and Phacoemulsification

Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques

19 Chapter 19: Cataract Anaesthesia and Surgical Complications

Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO

20 Chapter 20: Corneal and Intraocular Refractive Surgery

Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange

21 Chapter 21: Presbyopia Procedures and Surface Therapeutics

Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin

22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy

Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation

23 Chapter 23: Angle, Disc and Visual-Field Assessment

Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry

24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms

Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure

25 Chapter 25: POAG, Angle Closure and Pigmentary Disease

POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma

26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment

Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers

27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion

Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions

28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy

Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis

29 Chapter 29: Inherited Retina and Electrophysiology

Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina

30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid

AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum

31 Chapter 31: Retinal Breaks and Detachment Repair

PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling

32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma

Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment

33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation

SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation

34 Chapter 34: Infectious Uveitis and Endophthalmitis

Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment

35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy

Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison

36 Chapter 36: Papilloedema, IIH and Afferent Localisation

Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization

37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology

Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies

38 Chapter 38: Central Motor Control and Cranial Nerve Palsies

Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus

39 Chapter 39: Myasthenia and Ocular Myopathy

Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome

40 Chapter 40: Pupillary Pathways and Anisocoria

Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials

41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment

Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation

42 Chapter 42: Lid Repair and Lacrimal Drainage

Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR

43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours

Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma

44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease

Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling

45 Chapter 45: Ocular Trauma and Vascular Systemic Disease

Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease

46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology

Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects

47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations

Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal

Paraneoplastic retinopathy, treatment effects and counselling

Key Takeaways Explain This Topic AI

Paraneoplastic visual loss can precede a known malignancy and occur without visible ocular metastases.

CAR antibodies and MAR ERG patterns support a clinical diagnosis but are not individually definitive.

BDUMP is a bilateral paraneoplastic uveal process requiring systemic malignancy assessment.

Cancer-treatment toxicity decisions require oncology coordination, realistic prognosis and rehabilitation.

Last updated: October 2026

Visual loss may arise away from the tumour

Paraneoplastic ocular disease results from an effect of a malignancy rather than direct invasion or ordinary metastasis. Cancer-associated retinopathy, melanoma-associated retinopathy and bilateral diffuse uveal melanocytic proliferation are important examples. Symptoms can precede a known cancer diagnosis. The eye may look relatively normal early despite serious functional loss, so unexplained bilateral photopsias, night blindness or field change deserves a structured assessment.

Ask about tempo, systemic symptoms, cancer history and treatment exposure. Measure acuity, colour and fields, examine the retina and obtain appropriate OCT and electrophysiology. Consider inherited degeneration, toxic retinopathy, nutritional disease and infection as alternatives. A temporal association with cancer is informative but does not prove a paraneoplastic mechanism.

CAR and MAR

Cancer-associated retinopathy (CAR) can affect photoreceptor function and present with photopsias, progressive field loss and reduced vision. Anti-retinal antibodies, including recoverin antibodies in selected cases, may support the assessment. Antibody testing has specificity and interpretation limitations: positive antibodies can occur outside the suspected syndrome, and a negative panel does not exclude every autoimmune retinal process.

Melanoma-associated retinopathy (MAR) often involves night blindness, photopsias and an electronegative ERG pattern reflecting ON-bipolar dysfunction. TRPM1-directed antibodies have been demonstrated in primary research. Distinguish the pattern from congenital stationary night blindness, retinoschisis and acquired vascular disease. Adult onset, melanoma context and the wider assessment help explain why the same ERG pattern can mean a different disease.

Coordinate cancer investigation or review with oncology. Treatment of the underlying malignancy and selected immunomodulation may be considered, but response is variable and no single antibody result guarantees benefit from a particular regimen. Follow both objective function and the patient's ability to navigate, read and cope with glare.

BDUMP

Bilateral diffuse uveal melanocytic proliferation (BDUMP) is a rare paraneoplastic syndrome with bilateral uveal changes, often rapid visual decline, characteristic RPE abnormalities, exudative detachments and cataract. Multiple pigmented or nonpigmented uveal lesions may appear. These findings should prompt consideration of an associated extraocular malignancy rather than an assumption of simultaneous independent ocular melanomas.

Use multimodal imaging and systemic investigation with specialist teams. Proposed treatments, including plasma exchange in selected reports, have limited and variable evidence. Do not describe a case-series response as a proven cure. Distinguish direct choroidal metastases and other causes of bilateral exudative change because their treatment strategies differ.

  • Syndrome Functional or structural clue Interpretive caution
  • CAR Photoreceptor dysfunction and visual-field loss Antibodies are not standalone proof
  • MAR Night symptoms and electronegative ERG Similar patterns occur in nonparaneoplastic disease
  • BDUMP Bilateral uveal proliferation and RPE change Requires systemic malignancy assessment
  • Treatment toxicity Relation to therapy and dose or timing Exclude tumour progression and other causes
  • Complications of cancer treatment

Radiation can cause retinopathy, macular oedema, cataract, optic neuropathy, surface injury and neovascular glaucoma according to the treated field and dose. The latency and clinical pattern matter. Anti-VEGF and other selected interventions may address complications, but visual outcome depends on the underlying tissue injury. New visual loss after radiotherapy should not automatically be attributed to radiation without excluding tumour recurrence or another emergency.

Systemic cancer therapies can produce inflammatory, vascular, surface and retinal effects. Immune checkpoint treatment can cause ocular inflammation, while targeted agents can have characteristic retinal fluid or other toxicity patterns. Coordinate diagnosis and decisions about continuing, pausing or altering treatment with oncology. The ophthalmologist should describe severity and risk, rather than independently withdrawing a life-prolonging medicine without a coordinated plan when consultation is possible.

Surgery and eye removal also have long-term effects, including refractive change, diplopia, socket problems and adaptation to monocular vision. Include rehabilitation and fellow-eye protection in follow-up. A stable tumour measurement alone does not establish that the patient's functional needs have been met.

Prognosis and informed discussion

Separate local tumour control, preservation of vision and systemic survival when explaining outcomes. Prognostic genetic or staging results estimate risk and have uncertainty; avoid converting a population percentage into a promise for an individual. Ask how much detail the patient wants and include support for anxiety, family concerns and work or driving implications.

A patient with rapid bilateral night-vision loss and melanoma needs electrophysiological and paraneoplastic assessment, not only a search for a visible metastasis. Another with new oedema after radiotherapy needs complication treatment and confirmation of tumour status. In both cases, state the mechanism, coordinate systemic care and provide rehabilitation while diagnostic work continues.

Sources: Primary MAR TRPM1 study , primary BDUMP study and EBO oncology curriculum .

Sections you finish are checked off in the contents.

  • Up Next
  • Trauma terminology and prognostic scoring
  • Chapter 45: Ocular Trauma and Vascular Systemic Disease